Lifeward (LFWD) Net Income towards Common Stockholders (2015 - 2026)
Lifeward's (LFWD) quarterly Net Income towards Common Stockholders came in at -$11.5 million in Q2 2026, down 75.54% year-over-year from -$47.1 million in Q2 2025, and down 6.73% quarter-over-quarter from -$10.8 million in Q1 2026.
Powered by 
Analysis
Lifeward (LFWD) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Lifeward has disclosed Net Income towards Common Stockholders across 12 years of filings, most recently posting -$11.5 million for Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders fell 75.54% year-over-year to -$11.5 million; the TTM figure through Jun 2026 stood at -$30.8 million (down 3.6% YoY), while the FY2025 annual figure was -$19.9 million, up 31.19% from the prior year.
- Net Income towards Common Stockholders came in at -$11.5 million for Q2 2026 at Lifeward, down from -$10.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.1 million in Q3 2024 to a low of -$15.3 million in Q4 2024.
- Average Net Income towards Common Stockholders over 5 years is -$6.3 million, with a median of -$5.3 million recorded in 2022.
- Year-over-year, Net Income towards Common Stockholders plunged 170.93% in 2024 and surged 65.0% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$5.3 million in 2022, then slipped by 6.14% to -$5.6 million in 2023, then sank by 170.93% to -$15.3 million in 2024, then surged by 65.0% to -$5.3 million in 2025, then slumped by 115.39% to -$11.5 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$11.5 million in Q2 2026, -$10.8 million in Q1 2026, and -$5.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Lifeward | 19.77 Mn | 10.32 Mn | 2.71 Mn | -11.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.52 Mn |
| Mar 31, 2026 | -10.79 Mn |
| Dec 31, 2025 | -5.35 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | -6.56 Mn |
| Mar 31, 2025 | -4.83 Mn |
| Dec 31, 2024 | -15.28 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Jun 30, 2024 | -4.30 Mn |
| Mar 31, 2024 | -6.28 Mn |
| Dec 31, 2023 | -5.64 Mn |
| Sep 30, 2023 | -7.53 Mn |
| Jun 30, 2023 | -4.64 Mn |
| Mar 31, 2023 | -4.32 Mn |
| Dec 31, 2022 | -5.31 Mn |
| Sep 30, 2022 | -5.46 Mn |
| Jun 30, 2022 | -4.45 Mn |
| Mar 31, 2022 | -4.35 Mn |
| Dec 31, 2021 | -3.86 Mn |
| Sep 30, 2021 | -2.68 Mn |